← board
ADMA
distress 0/10 · well-funded / low risk$8.33-1%today-59% from 52w high
Lead: primary or secondary immunodeficiencies
Revenue
$114M
Liquidity
$138M
Runway
—
Shares 1y
-3%
Price & events
-52.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.6%
1D
-5.4%
1W
-4.1%
1M
-24.8%
3M
-50.2%
6M
-51.6%
1Y
-39.5%
2Y
+417.4%
5Y
+294.8%
All
Overview
- Market Cap
- $1.93B
- Enterprise Value
- $1.99B
- Volume
- 140.57K
- 52 Week Range
- $7.60 – $20.38
- Total Shares
- 231.77M
- Float Shares
- 226.72M
- Short %
- 12.79%
- % Held by Insiders
- 1.87%
- % Held by Institutions
- 93.83%
- RVOL
- 0.04x
- Beta
- 0.73
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- 2026Guided 40%regulatory submissionFiled (NDA/BLA)SG-001 · Anticipated FDA Pre-IND submission for SG-001 in 2026.SEC 8-K
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- May 2026conferencedata presentationsecondaryASCENIV · Positive, statistically significant real-world ASCENIV outcomes to be presented at CIS in May 2026.SEC 8-K
- 2025-12-01partnershipASCENIV · Divestiture of three plasma centers and entered into long-term plasma supply agreements in December 2025.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $17 (+104% upside) · 5 analysts
- 2026-07-15MizuhoOutperform
- 2026-05-07Canaccord GenuityBuy
- 2026-05-07MizuhoOutperform
- 2026-04-21Canaccord GenuityBuy
- 2026-04-13MizuhoOutperform
- 2026-03-26Cantor FitzgeraldOverweight → Neutral
Competitors — primary or secondary immunodeficiencies
- none identified
Recent news
- 2026-07-23Lost Money on ADMA BIOLOGICS, INC. (ADMA)? Join Class Action Suit Seeking Recovery - Contact SueWallSt - PR Newswire
- 2026-07-23ADMA Alert: ADMA Biologics, Inc. (NASDAQ: ADMA) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed - PR Newswire
- 2026-07-23ADMA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
- 2026-07-23How (ADMA) Movements Inform Risk Allocation Models - Stock Traders Daily
- 2026-07-22ADMA Deadline: ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - The Conway Daily Sun
- 2026-07-22ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - The Globe and Mail
- 2026-07-22ADMA Deadline Alert: Levi & Korsinsky Reminds ADMA BIOLOGICS, INC. (ADMA) Investors of Securities Class Action Deadline on August 10, 2026 - PR Newswire
- 2026-07-21Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.